MANTECH Publications
International Journal of Drug Formulation, Development & Research
Volume 4, Issue 1, January-June 2026

Novel Nanoparticle-Based Drug Delivery Systems

Dr. Hetal R. Shah[1], Jignesh K. Patel[2], Krupa D. Mehta[3]
Associate Professor[1], Students[2, 3]
Department of Pharmaceutical Sciences
L.M. College of Pharmacy
***Corresponding Author Email**:hetal.shah43@gmail.com[1]*
***DOI:** https://doi.org/10.5281/zenodo.19708402*

ABSTRACT

The advent of nanoparticle-based drug delivery systems has revolutionized modern therapeutics by enhancing drug bioavailability, specificity, and controlled release while minimizing systemic toxicity. Nanoparticles (NPs) possess unique physicochemical properties such as high surface area-to-volume ratio, tunable size, and surface functionalization potential, which enable targeted drug delivery and improved pharmacokinetics. This review highlights the recent advances in nanoparticle-based drug delivery, including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and hybrid nanostructures. The paper further discusses strategies for targeted delivery, stimuli-responsive systems, and clinical applications across oncology, infectious diseases, and neurodegenerative disorders. Challenges in large-scale production, biocompatibility, and regulatory approval are also addressed. Future perspectives focus on integrating nanotechnology with personalized medicine for more efficient and safer therapeutics.

***KEYWORDS:**Nanoparticles, Drug delivery, Targeted therapy, Liposomes, Polymeric nanoparticles, Dendrimers, Stimuli-responsive, Pharmacokinetics*

INTRODUCTION

Conventional drug delivery methods often suffer from poor bioavailability, non-specific distribution, rapid clearance, and adverse side effects. The development of nanoparticle-based drug delivery systems (NDDS) offers a promising solution to these challenges. Nanoparticles, typically ranging from 1–100 nm in size, exhibit unique properties, including enhanced

solubility of hydrophobic drugs, protection of labile therapeutic agents, and potential for surface modification for targeted delivery. The convergence of nanotechnology and pharmaceutical sciences has led to the creation of multifunctional nanocarriers capable of precise drug delivery, controlled release, and real-time tracking in vivo.

Historical Perspective

The concept of using nanocarriers for drug delivery emerged in the 1960s with the development of liposomes. Over the past decades, significant progress has been made, encompassing polymeric nanoparticles, metallic nanostructures, dendrimers, and hybrid systems. The clinical translation of nanoparticle therapeutics has been exemplified by FDA-approved formulations such as Doxil® (liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel), demonstrating enhanced efficacy and reduced toxicity.

TYPES OF NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS

1. Liposomes

Liposomes are **spherical, self-assembled vesicles** consisting of one or more phospholipid bilayers enclosing an aqueous core. Their structural versatility allows them to carry **hydrophilic drugs** within the aqueous core and **hydrophobic drugs** within the lipid bilayer, making them highly adaptable for various therapeutic applications. The amphiphilic nature of phospholipids, such as phosphatidylcholine and phosphatidylserine, drives the spontaneous formation of these bilayered vesicles in aqueous environments.

a) Structure and Classification

Liposomes can be classified based on size and the number of bilayers:

- **Small Unilamellar Vesicles (SUVs):** 20–100 nm, single lipid bilayer; commonly used for intravenous drug delivery due to their small size and prolonged circulation.
- **Large Unilamellar Vesicles (LUVs):** 100–1000 nm, single bilayer; suitable for encapsulating larger quantities of hydrophilic drugs.
- **Multilamellar Vesicles (MLVs):**>500 nm, multiple concentric bilayers; often used for sustained release formulations.

Their size, surface charge, and lipid composition directly influence **biodistribution, circulation time, and cellular uptake**.

b) Mechanism of Drug Delivery

Liposomes deliver drugs through several mechanisms:

1. **Passive Targeting:** Exploiting the enhanced permeability and retention (EPR) effect in tumors, liposomes accumulate in leaky vasculature and release the drug locally.
2. **Active Targeting:** Surface modification with ligands such as antibodies, peptides, or small molecules facilitates receptor-mediated endocytosis by specific cells.
3. **Controlled Release:** Lipid composition can be tuned to allow slow drug release over time, maintaining therapeutic concentrations without frequent dosing.

c) Surface Modification

To improve therapeutic efficacy, liposomes can be **surface-engineered**:

- **PEGylation:** Attaching polyethylene glycol (PEG) creates "stealth liposomes" that evade detection and clearance by the **reticuloendothelial system (RES)**, prolonging circulation.
- **Ligand Conjugation:** Antibodies or folate molecules on the liposome surface allow **active targeting** to cancer cells or inflamed tissues.
- **PH-sensitive Liposomes:** These release drugs in response to acidic environments (e.g., tumor tissue or intracellular lysosomes), enhancing localized drug delivery.

d) Advantages of Liposomes

- **Biodegradable and Biocompatible:** Composed of naturally occurring phospholipids, liposomes are metabolized into non-toxic components.
- **Versatile Drug Loading:** Can encapsulate both hydrophilic and hydrophobic molecules, as well as nucleic acids and proteins.
- **Reduced Systemic Toxicity:** Targeted and controlled release minimizes off-target effects.
- **Improved Pharmacokinetics:** Modifications like PEGylation extend half-life in circulation.

e) Challenges

Despite their potential, liposomes face certain limitations:

- **Stability Issues:** Prone to lipid oxidation, hydrolysis, and aggregation during storage, which may reduce efficacy.
- **High Production Cost:** Sophisticated techniques such as extrusion, microfluidics, or

freeze-drying are required for reproducible formulations.

- **Rapid Clearance without Modification:** Unmodified liposomes are quickly cleared by the RES.
- **Limited Drug Loading for Hydrophobic Molecules:** While lipophilic drugs can embed in bilayers, excessively hydrophobic drugs may destabilize the liposome.

2. Polymeric Nanoparticles

Polymeric nanoparticles (PNPs) are solid colloidal particles ranging from **10 to 1000 nm** in size, fabricated from natural or synthetic polymers. They have emerged as versatile drug delivery carriers due to their **biodegradability, biocompatibility, and tunable physicochemical properties**. PNPs can encapsulate, adsorb, or conjugate drugs, allowing precise control over drug release, improved solubility, and enhanced pharmacokinetics.

a) Types of Polymeric Nanoparticles

- **Nanocapsules:** Drug is confined within a cavity surrounded by a polymeric shell, providing **controlled release** and protection from degradation.
- **Nanospheres:** Drugs are uniformly dispersed or adsorbed throughout the polymer matrix, allowing **sustained drug release**.

Polymers Used:

- **Synthetic polymers:** PLGA (poly(lactic-co-glycolic acid)), PLA (polylactic acid), PCL (polycaprolactone)
- **Natural polymers:** Chitosan, alginate, gelatin, albumin

The choice of polymer influences **drug loading capacity, release kinetics, biodegradability, and targeting potential**.

b) Mechanism of Drug Delivery

Polymeric nanoparticles deliver drugs via multiple mechanisms:

Controlled and Sustained Release:

- Drug is slowly released through **diffusion, polymer degradation, or swelling** of the polymer matrix.

- This minimizes peak plasma levels, reducing toxicity and enhancing efficacy.

Targeted Delivery:

- Surface functionalization with **ligands, antibodies, or peptides** enables **receptor-mediated endocytosis** in target cells.
- PEGylation increases circulation time and reduces clearance by the RES.

Protection of Labile Drugs:

- PNPs shield sensitive molecules such as proteins, peptides, or nucleic acids from enzymatic degradation or hydrolysis.

c) Advantages of Polymeric Nanoparticles

- **Biodegradability and Biocompatibility:** Synthetic polymers like PLGA degrade into lactic and glycolic acids, naturally metabolized by the body.
- **Versatile Drug Loading:** Can deliver hydrophilic, hydrophobic, or macromolecular drugs including DNA and RNA.
- **Controlled Release:** Release profiles can be tailored by altering polymer composition, molecular weight, and nanoparticle size.
- **Targeted Therapy:** Surface modifications enable precise drug delivery, reducing off-target effects.
- **Enhanced Bioavailability:** Poorly soluble drugs gain improved solubility when encapsulated in polymeric carriers.

d) Challenges

- **Burst Release:** Initial rapid release of drugs may occur if poorly encapsulated.
- **Polymer Residue Toxicity:** Some synthetic polymers or surfactants used during formulation may induce cytotoxicity.
- **Complex Fabrication:** Techniques like emulsion-solvent evaporation, nanoprecipitation, or spray drying require precise control over parameters to ensure reproducibility.
- **Stability Issues:** Nanoparticles can aggregate or undergo hydrolysis during storage, affecting efficacy

Table 1: Representative polymeric nanoparticles and their applications

Polymer	Drug	Application	Targeting Strategy
PLGA	Paclitaxel	Cancer therapy	Ligand-mediated targeting
Chitosan	Insulin	Oral delivery	pH-responsive coating
PLA	Curcumin	Anti-inflammatory	PEGylation for stability

DENDRIMERS

Dendrimers are **synthetic, highly branched, tree-like macromolecules** characterized by a **monodisperse and well-defined architecture**. They consist of three key structural components:

1. **Core:** The central molecule from which branches originate.
2. **Branches (Interior Generations):** Repeated layers of monomer units that increase molecular size with each generation.
3. **Surface Functional Groups (Exterior Generations):** Terminal groups that can be chemically modified for drug conjugation, targeting, or solubility enhancement.

The **multivalent surface** allows dendrimers to carry multiple drug molecules, targeting ligands, or imaging agents simultaneously, making them excellent platforms for **multifunctional drug delivery**.

1. Mechanism of Drug Delivery

- **Encapsulation:** Hydrophobic drugs can be sequestered within the internal cavities of dendrimers, protecting them from degradation and improving solubility.
- **Conjugation:** Drugs or ligands can be covalently attached to terminal functional groups for **controlled release** and **targeted therapy**.
- **Targeted Cellular Uptake:** Surface functionalization with molecules like folate, peptides, or antibodies facilitates receptor-mediated endocytosis in tumor or diseased cells.

2. Advantages of Dendrimers

- **High Drug-Loading Capacity:** Interior cavities and surface groups allow multiple drug molecules to be carried per dendrimer.

- **Precise Molecular Architecture:** Monodisperse structure enables predictable pharmacokinetics and reproducible synthesis.
- **Targeted Therapy Potential:** Surface functionalization allows selective binding to specific cell types, reducing off-target toxicity.
- **Versatility:** Can deliver small molecules, nucleic acids, proteins, and imaging agents.

3. Challenges

- **Cytotoxicity:** Cationic dendrimers may disrupt cell membranes, leading to cytotoxic effects. Surface modification (e.g., PEGylation) can reduce toxicity.
- **Complex and Costly Synthesis:** Multiple iterative steps are required to generate high-generation dendrimers, making large-scale production challenging.
- **Limited Clinical Translation:** Despite promising preclinical results, few dendrimer-based therapeutics have reached the market.

4. Applications

- **Oncology:** Dendrimers can deliver chemotherapeutics like doxorubicin directly to tumor cells.
- **Gene Delivery:** Cationic dendrimers complex with DNA or siRNA to protect nucleic acids and facilitate cellular uptake.
- **Imaging:** Conjugation with fluorescent dyes or MRI contrast agents enables real-time tracking and theranostic applications.

5. Recent Advances

- **Stimuli-Responsive Dendrimers:** Release drugs in response to pH, redox conditions, or enzymes in diseased tissues.
- **Multifunctional Dendrimers:** Co-delivery of drugs and imaging agents for simultaneous therapy and diagnostics.
- **Surface Engineering:**PEGylation and ligand conjugation improve circulation, targeting, and reduce immunogenicity.

METALLIC NANOPARTICLES

Metallic nanoparticles (MNPs) are particles composed of metals such as **gold (AuNPs), silver (AgNPs), and iron oxide (IONPs)**, typically 1–100 nm in size. Their **unique optical, electronic, and magnetic properties** make them ideal for **theranostics, targeted**

therapy,and imaging applications.

1. **Mechanism of Drug Delivery**

- **Drug Conjugation or Adsorption:** Drugs, peptides, or antibodies can be attached to the nanoparticle surface via covalent bonds or electrostatic interactions.
- **Photothermal Therapy:** Gold nanoparticles absorb near-infrared (NIR) light and convert it into heat, killing tumor cells locally.
- **Magnetic Targeting:** Iron oxide nanoparticles can be guided using external magnetic fields for targeted delivery and localized therapy.
- **Antimicrobial Action:** Silver nanoparticles generate reactive oxygen species (ROS) and disrupt microbial membranes.

2. **Advantages of Metallic Nanoparticles**

- **Theranostic Potential:** Can combine therapy and imaging in a single platform.
- **Surface Functionalization:** Ligands, drugs, or polymers can be attached to improve targeting and reduce toxicity.
- **Unique Physical Properties:** Plasmon resonance (AuNPs), magnetic responsiveness (IONPs), and antimicrobial activity (AgNPs) enable diverse applications.
- **Rapid Cellular Uptake:** Small size facilitates penetration into tissues and cellular internalization.

3. **Challenges**

- **Cytotoxicity and Biocompatibility:** Some MNPs, particularly silver and high-dose iron oxide, may induce oxidative stress or inflammatory responses.
- **Aggregation:** Metallic nanoparticles can aggregate in physiological media, reducing efficacy and stability.
- **Clearance and Biodistribution:** Metal nanoparticles may accumulate in the liver, spleen, or kidneys, raising long-term safety concerns.
- **Cost and Scalability:** Synthesis of uniform, monodisperse nanoparticles can be expensive.

4. **Applications**

a) **Photothermal Therapy (Gold Nanoparticles):**

- Gold nanoparticles absorb NIR light to produce localized heating, selectively killing

cancer cells.

b) Magnetic Resonance Imaging (Iron Oxide Nanoparticles):

- IONPs act as contrast agents for MRI and can be magnetically guided to target tissues.

c) Antimicrobial Therapy (Silver Nanoparticles):

- AgNPs demonstrate broad-spectrum antimicrobial activity against bacteria, viruses, and fungi.

d) Drug Delivery:

- MNPs can carry chemotherapeutics, genes, or siRNA, allowing site-specific release and combination therapies.

5. Recent Advances

- **Hybrid Metallic Nanoparticles:** Combining gold or silver with polymers or lipids to enhance stability and drug delivery potential.
- **Stimuli-Responsive Systems:** Light, magnetic field, or pH triggers controlled drug release.
- **Theranostic Platforms:** MNPs designed for simultaneous imaging, drug delivery, and photothermal therapy.



Figure 1: Gold nanoparticle-mediated targeted drug delivery and photothermal therapy

Hybrid Nanostructures

Hybrid nanoparticles combine features of different nanocarriers to achieve multifunctionality. Examples include lipid-polymer hybrid nanoparticles, which offer the stability of polymers and the biocompatibility of lipids. These systems are particularly effective for co-delivery of drugs and nucleic acids.

STRATEGIES FOR TARGETED DRUG DELIVERY

1. Passive Targeting

Exploits the enhanced permeability and retention (EPR) effect, which allows nanoparticles to accumulate preferentially in tumor tissues due to leaky vasculature and poor lymphatic drainage.

2. Active Targeting

Involves functionalizing nanoparticles with ligands such as antibodies, peptides, or small molecules that bind to specific receptors on target cells. Examples include folate-conjugated nanoparticles targeting folate receptor-overexpressing tumors.

3. Stimuli-Responsive Systems

Nanocarriers can be engineered to release drugs in response to internal stimuli (pH, redox potential, enzymes) or external stimuli (temperature, light, and magnetic field), ensuring site-specific delivery and minimizing systemic side effects.

Table 2: Examples of stimuli-responsive nanoparticle systems.

Nanoparticle Type	Stimulus	Drug	Application
Lipid-based	pH-sensitive	Doxorubicin	Tumor targeting
Polymer-based	Redox-sensitive	Cisplatin	Cancer therapy
Gold NP	NIR light	Paclitaxel	Photothermal therapy

CLINICAL APPLICATIONS

1. Oncology

Nanoparticles enhance the therapeutic index of chemotherapeutics while reducing systemic toxicity. FDA-approved formulations like Doxil® and Abraxane® illustrate the success of nanoparticle-mediated drug delivery in cancer therapy.

2. Infectious Diseases

Nanoparticles improve solubility, stability, and bioavailability of antimicrobial drugs. Liposomal amphotericin B and polymeric nanoparticles for antiretrovirals have demonstrated enhanced efficacy and patient compliance.

3. Neurological Disorders

Crossing the blood-brain barrier (BBB) remains challenging. Nanoparticles, particularly PEGylated and ligand-conjugated systems, show promise for delivering drugs for Alzheimer's, Parkinson's, and glioblastoma.

CHALLENGES IN NANOPARTICLE-BASED DRUG DELIVERY

- **Toxicity and Immunogenicity:** Some nanoparticles, particularly cationic and metallic types, can induce cytotoxicity and immune responses.
- **Stability and Aggregation:** Nanoparticles may aggregate in biological fluids, reducing efficacy.
- **Scale-up and Manufacturing:** Complex synthesis and quality control hinder large-scale production.
- **Regulatory Approval:** Regulatory guidelines for NDDS are still evolving, complicating clinical translation.

FUTURE PERSPECTIVES

The integration of nanoparticles with **personalized medicine**, **CRISPR-based gene editing**, and **theranostics** is expected to enhance therapeutic precision. Artificial intelligence-guided nanoparticle design may accelerate optimization for pharmacokinetics, targeting efficiency, and safety. Multifunctional nanocarriers capable of simultaneous imaging, therapy, and monitoring will play a pivotal role in next-generation therapeutics.

CONCLUSION

Nanoparticle-based drug delivery systems represent a paradigm shift in modern therapeutics, offering targeted, controlled, and efficient drug delivery. Despite challenges in toxicity, stability, and regulatory hurdles, advances in nanotechnology, surface functionalization, and stimuli-responsive design are rapidly overcoming these barriers. The future of NDDS lies in multifunctional, personalized nanomedicine, which holds the potential to improve patient

outcomes across oncology, infectious diseases, and neurological disorders. Continued interdisciplinary research will be crucial in translating these systems from bench to bedside.

REFERENCES

1. Allen, T.M., Cullis, P.R. Drug delivery systems: Entering the mainstream. *Science*, 303(5665), 1818–1822 (2004).
2. Peer, D., et al. Nanocarriers as an emerging platform for cancer therapy. *Nat. Nanotechnol.*, 2, 751–760 (2007).
3. Zhang, L., Gu, F.X., et al. Nanoparticles in medicine: Therapeutic applications and developments. *Clin. Pharmacol. Ther.*, 83, 761–769 (2008).
4. Torchilin, V.P. Multifunctional nanocarriers. *Adv. Drug Deliv. Rev.*, 58, 1532–1555 (2006).
5. Farokhzad, O.C., Langer, R. Impact of nanotechnology on drug delivery. *ACS Nano*, 3, 16–20 (2009).
6. Rzigalinski, B.A., Strobl, J.S. Cadmium-containing nanoparticles: Perspectives in cancer therapy. *Toxicol. Appl. Pharmacol.*, 217, 200–207 (2006).
7. Bozzuto, G., Molinari, A. Liposomes as nanomedical devices. *Int. J. Nanomed.*, 10, 975–999 (2015).
8. Kesharwani, P., et al. Dendrimer-mediated drug delivery for cancer therapy. *Drug Discov. Today*, 19(10), 140–149 (2014).
9. Liu, Y., Miyoshi, H., Nakamura, M. Nanomedicine for drug delivery and imaging: A promising approach for cancer therapy. *Cancer Sci.*, 96, 875–881 (2005).
10. Singh, R., Lillard, J.W. Nanoparticle-based targeted drug delivery. *Exp. Mol. Pathol.*, 86, 215–223 (2009).

Cite as:

Dr. Hetal R. Shah, Jignesh K. Patel, Krupa D. Mehta (2026). Novel Nanoparticle-Based Drug Delivery Systems. International Journal of Drug Formulation, Development & Research, 4(1) 42-53.
https://doi.org/10.5281/zenodo.19708402